{"a":[{"_":"Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic ","$":{"href":"/pharma/booming-dupixent-sales-fuel-regenerons-biggest-quarter-pandemic","hreflang":"en"}}]}

Summary

Regeneron and Sanofi's Dupixent achieved $6 billion in worldwide sales during Q2 2026, marking the first time the drug reached this milestone with a 38% increase year-over-year, representing Regeneron's strongest quarter since the pandemic.